Beamr video compression achieves up to 50% improvement for AVs
RICHMOND, Va. - Pharmaceutical (TADAWUL:2070) company Indivior PLC (NASDAQ:LSE: LON:INDV), currently valued at $1.16 billion, announced today that it will reduce its Board of Directors to seven members, with all directors standing for re-election at the upcoming 2025 Annual General Meeting (AGM). According to InvestingPro data, management has been actively buying back shares, demonstrating confidence in the company’s direction despite recent stock price volatility. This decision comes after a series of appointments and departures, including the stepping down of Robert Schriesheim as an Independent (LON:IOG) Non-Executive Director on March 2, 2025, and the decision by Peter Bains and Jo LeCouilliard not to stand for re-election.
The company, which transitioned to a US primary listing in 2024, is also set to appoint a new Independent Non-Executive Director by July 1, 2025, a choice that will be subject to approval by Oaktree Capital Management L.P., a significant shareholder. Trading at $9.55, InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets between $15-16 per share. If the appointment is not made by the deadline, Oaktree has the right to nominate another Non-Executive Director, which would increase the Board to eight members post-AGM.
Further changes include Daniel Ninivaggi taking over as Chair of the Nomination Committee on March 10, 2025, and Barbara Ryan succeeding Jo LeCouilliard as Chair of the Compensation Committee, effective from the end of the AGM. Additionally, the Company’s Operational Committee will be discontinued.
Dr. David Wheadon, Chair of Indivior, expressed gratitude to the departing board members for their commitment to the company’s mission of providing therapeutic interventions to patients with opioid use disorder.
These governance adjustments are part of an amended and restated Relationship Agreement between Indivior and Oaktree, which includes mutual support obligations and undertakings.
Indivior is dedicated to developing treatments for substance use disorders, aiming to transform the condition from a global crisis to a recognized and treated chronic disease. The company, headquartered in the United States, operates globally with a portfolio of opioid use disorder treatments and a pipeline of product candidates. With an impressive gross profit margin of 83.33% and moderate debt levels, the company maintains strong operational efficiency. For deeper insights into Indivior’s financial health and growth prospects, InvestingPro offers comprehensive analysis through its detailed Pro Research Report, available alongside 10+ additional ProTips and extensive financial metrics.
The information in this article is based on a press release statement from Indivior PLC.
In other recent news, Indivior PLC reported its fourth-quarter 2024 earnings, showcasing a notable performance by surpassing analyst expectations. The company achieved earnings per share (EPS) of $0.32, exceeding the anticipated $0.26, and reported net revenue of $298 million, which was above the forecasted $261.33 million. Despite these positive results, Indivior’s shares experienced a decline, reflecting investor concerns over future guidance and market conditions. Indivior’s flagship product, SUBLOCADE, contributed significantly to the revenue growth, with a 20% increase in net revenue year-over-year, reaching $756 million for the full year. Looking ahead to 2025, Indivior has projected total net revenue between $955 million and $1,025 million, identifying the upcoming year as a transition period. Analyst firms such as Piper Sandler have noted the potential challenges Indivior may face, particularly with the anticipated decline in SUBOXONE Film sales due to increased generic competition. Additionally, Indivior has been actively addressing legacy litigation issues, further stabilizing its financial standing. These developments indicate the company’s strategic focus on sustaining growth and navigating market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.